Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
CMMB moved a median of 0.00% 30 minutes after news, and -0.28% by the close. How CMMB actually reacts to news — the realized, point-in-time move the market made, measured across 159 labeled events over the last three years with zero look-ahead.
CMMB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 150 |
| 30-min | 0.00% | 47% | 155 |
| 60-min | -0.26% | 48% | 158 |
| to close | -0.28% | 41% | 156 |
| Middle 50% of CMMB reactions | -1.80% to +2.04% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 159 |
Half of all Chemomab Therapeutics Ltd. - American Depositary Shares news events land between -1.80% and +2.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CMMB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CMMB's baseline. Nothing else.
Recent CMMB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Chemomab Therapeutics For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +2.40% | +4.00% | |
| Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference | Press release | GlobeNewswire | +2.96% | +0.74% | |
| Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.57% | +6.63% | |
| Form 6-K Chemomab Therapeutics For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.57% | +6.63% | |
| Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis | Press release | GlobeNewswire | -8.66% | -14.72% | |
| Form 6-K Chemomab Therapeutics For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | -8.66% | -14.72% | |
| Form 6-K Chemomab Therapeutics For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | +3.45% | -1.15% | |
| Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.15% | -0.58% | |
| Form 6-K Chemomab Therapeutics For: May 14 | SEC filing · Form 6-K | SEC EDGAR | +3.15% | -0.58% | |
| Form 6-K Chemomab Therapeutics For: May 06 | SEC filing · Form 6-K | SEC EDGAR | -0.27% | -5.43% | |
| Form 6-K Chemomab Therapeutics For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | -1.39% | -5.81% | |
| Form 20-F Chemomab Therapeutics For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +3.02% | -5.99% | |
| Form 6-K Chemomab Therapeutics For: Mar 20 | SEC filing · Form 6-K | SEC EDGAR | -0.28% | -6.14% | |
| Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +0.25% | -3.50% | |
| Form 6-K Chemomab Therapeutics For: Mar 19 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | -3.50% | |
| Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -3.22% | -2.58% | |
| Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | +0.00% | +2.02% | |
| Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology | Press release | GlobeNewswire | -2.43% | -5.24% | |
| Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit | Press release | GlobeNewswire | +0.00% | -2.82% | |
| Form 6-K Chemomab Therapeutics For: Nov 21 | SEC filing · Form 6-K | SEC EDGAR | -2.21% | +1.61% | |
| Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.54% | -11.64% | |
| Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis | Press release | GlobeNewswire | +1.26% | -4.09% | |
| Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | +1.29% | +2.30% | |
| Form 6-K Chemomab Therapeutics For: Aug 22 | SEC filing · Form 6-K | SEC EDGAR | -1.01% | -2.15% | |
| Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.55% | -2.21% | |
| Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.45% | -4.86% | |
| Form 6-K Chemomab Therapeutics For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.45% | -4.86% | |
| IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight | Press release | PR Newswire | -0.53% | — | |
| THR-ß Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight | Press release | PR Newswire | +5.14% | +0.00% | |
| Form 6-K Chemomab Therapeutics For: Jul 25 | SEC filing · Form 6-K | SEC EDGAR | -5.74% | -6.84% | |
| Form 6-K Chemomab Therapeutics For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.86% | |
| Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25 | Press release | GlobeNewswire | -1.68% | -2.52% | |
| Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis | Press release | GlobeNewswire | -0.78% | -6.04% | |
| Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis | Press release | GlobeNewswire | +0.00% | -0.74% | |
| Form 6-K Chemomab Therapeutics For: May 27 | SEC filing · Form 6-K | SEC EDGAR | +2.14% | -2.14% | |
| Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.60% | +8.40% | |
| Form 6-K Chemomab Therapeutics For: May 15 | SEC filing · Form 6-K | SEC EDGAR | -1.60% | +8.40% | |
| Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight | Press release | PR Newswire | +1.13% | -4.72% | |
| Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 | Press release | GlobeNewswire | -0.51% | -7.64% | |
| Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases | Press release | GlobeNewswire | +0.67% | -4.29% | |
| Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences | Press release | GlobeNewswire | +0.00% | +3.57% | |
| Chemomab Announces New Medical and Clinical Appointments | Press release | GlobeNewswire | +0.00% | +0.83% | |
| Form 6-K Chemomab Therapeutics For: Apr 15 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.83% | |
| Form 20-F Chemomab Therapeutics For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +9.18% | +4.08% | |
| Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers | Press release | GlobeNewswire | -2.22% | -18.52% | |
| Form 6-K Chemomab Therapeutics For: Mar 27 | SEC filing · Form 6-K | SEC EDGAR | -2.22% | -18.52% | |
| Form 6-K Chemomab Therapeutics For: Mar 20 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.79% | |
| New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis | Press release | GlobeNewswire | +0.00% | +5.71% | |
| Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +2.45% | -7.36% | |
| Form 6-K Chemomab Therapeutics For: Mar 03 | SEC filing · Form 6-K | SEC EDGAR | +2.45% | -7.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CMMB section they belong to.
Where else CMMB is measured.
CMMB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Chemomab Therapeutics Ltd. - American Depositary Shares's median reaction calculated?
Every labeled CMMB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 159 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of CMMB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CMMB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.